CNS Pharmaceuticals annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
CNS Pharmaceuticals Depreciation & Amortization Growth & History (CNSP)
CNS Pharmaceuticals's depreciation and amortization was $3,918 for fiscal 2025.
View full CNS Pharmaceuticals company overviewCNS Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3,918 | $612 | +18.51% |
| 2024 | 2024-12-31 | $3,306 | −$828 | −20.03% |
| 2023 | 2023-12-31 | $4,134 | −$7,622 | −64.83% |
| 2022 | 2022-12-31 | $11,756 | −$1,314 | −10.05% |
| 2021 | 2021-12-31 | $13,070 | $1,974 | +17.79% |
| 2020 | 2020-12-31 | $11,096 | $9,141 | +467.57% |
| 2019 | 2019-12-31 | $1,955 | $1,955 | — |
| 2018 | 2018-12-31 | $0 | — | — |
CNS Pharmaceuticals quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11,132 | $10,232 | +1136.89% |
| Q1 2026 | 2026-03-31 | $1,868 | $768 | +69.82% |
| Q4 2025 | 2025-12-31 | $1,020 | — | — |
| Q3 2025 | 2025-09-30 | $898 | $147 | +19.57% |
| Q2 2025 | 2025-06-30 | $900 | $148 | +19.68% |
| Q1 2025 | 2025-03-31 | $1,100 | $282 | +34.47% |
| Q3 2024 | 2024-09-30 | $751 | −$148 | −16.46% |
| Q2 2024 | 2024-06-30 | $752 | −$251 | −25.02% |
| Q1 2024 | 2024-03-31 | $818 | −$461 | −36.04% |
| Q3 2023 | 2023-09-30 | $899 | −$1,895 | −67.82% |
| Q2 2023 | 2023-06-30 | $1,003 | −$2,203 | −68.71% |
| Q1 2023 | 2023-03-31 | $1,279 | −$2,096 | −62.10% |
| Q3 2022 | 2022-09-30 | $2,794 | −$575 | −17.07% |
| Q2 2022 | 2022-06-30 | $3,206 | −$4 | −0.12% |
| Q1 2022 | 2022-03-31 | $3,375 | $377 | +12.58% |
| Q3 2021 | 2021-09-30 | $3,369 | $206 | +6.51% |
| Q2 2021 | 2021-06-30 | $3,210 | $338 | +11.77% |
| Q1 2021 | 2021-03-31 | $2,998 | $1,081 | +56.39% |
| Q3 2020 | 2020-09-30 | $3,163 | $2,465 | +353.15% |
| Q2 2020 | 2020-06-30 | $2,872 | $2,705 | +1619.76% |
| Q1 2020 | 2020-03-31 | $1,917 | $1,917 | — |
| Q3 2019 | 2019-09-30 | $698 | — | — |
| Q2 2019 | 2019-06-30 | $167 | — | — |
| Q1 2019 | 2019-03-31 | $0 | — | — |
CNS Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, CNS Pharmaceuticals's depreciation and amortization decreased from $11,096 to $3,918, a change of −$7,178. The latest reported quarter, Q2 2026, shows $11,132.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNS Pharmaceuticals source filings ↗